New data supports clinical role of Cambridge Heart’s MTWA test in managing patients a
 

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that results of a prospective, 155-patient trial reinforce the value of the Microvolt T-Wave Alternans (MTWA) test as a predictor of life-threatening heart rhythms and Sudden Cardiac Death (SCD).

More...